Yakira Capital urges Atrium Therapeutics to launch strategic review, curb cash spending

Shareholder Yakira Capital Management is urging Atrium Therapeutics to launch a strategic review, curb cash spending and explain its dilutive financing, citing a 44% stock decline and a $50M dilutive financing.

Detected & updated continuously · Source: Nebula